Dernières nouvelles pour NextCure (NASDAQ:NXTC) Stock

NEXTCURE INC

NextCure

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

NextCure Inc

Mizuho analyst Siti Panigrahi maintains Cadence Design Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Outperform and raises the price target from $360 to $375.

News

Price Target

Analyst Ratings

CDNS

Mizuho Maintains Outperform on Cadence Design Systems, Raises Price Target to $375

Mizuho analyst John Roberts maintains Olin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) with a Neutral and lowers the price target from $24 to $23.

Mizuho Maintains Neutral on Olin, Lowers Price Target to $23

Flowserve (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) Sales for 2025 FY is expected to up by 3 to 4% YoY

Guidance

Flowserve Sales for 2025 FY is expected to up by 3 to 4% YoY

Mizuho analyst Dan Dolev maintains Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) with a Outperform and lowers the price target from $194 to $165.

Mizuho Maintains Outperform on Fiserv, Lowers Price Target to $165

The S&amp;P 500 has reached an unprecedented level of concentration, with the top 10 stocks driving 54% of its market cap gains since January 2021, according to the Kobeissi Letter.
What Happened: This means that out of a 70% total gain, would have come from just the top 10 companies, including giants like Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
These 10 firms now account for a near-record 39% of the S&amp;P 500's total market value, a level last seen during the <a href="https://www.benzinga.com/markets/tech/25/07/46551879/ai-bubble-is-more-unhinged-than-dot-com-a-chilling-warning-from-the-inside">2000 tech bubble</a>, raising concerns about market stability. 
The Kobeissi Letter highlights that this concentration has turbocharged returns but left the remaining 490 stocks contributing less than half the index's growth.
If you invested $100,000 on Jan. 1, 2021, your portfolio would have grown to $170,000, with $37,800 of that gain tied to these mega-caps.
The trend, fueled by passive investing and AI sector dominance, mirrors historical patterns like the dot-com era, where concentrated gains preceded a crash.
The Kobeissi Letter warns that such narrow rallies mask broader market fragility, with global investors increasingly shifting funds to emerging markets amid U.S. tech inflation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The stock market is more concentrated than ever: The top 10 stocks have accounted for ~54% of the S&amp;P 500&#39;s market cap gains since 2021. In other words, 37.8 percentage points of the S&amp;P 500's +70% gain came from the 10 largest companies. If you had invested $100,000 in the… <a href="https://t.co/B7rPk7QEsd">pic.twitter.com/B7rPk7QEsd</a>
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1949975405462524389?ref_src=twsrc%5Etfw">July 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46679779/opendoor-skyrockets-314-in-a-month-amid-meme-stock-mania-hedge-fund-manager-who-reaped-windfall-gains-says-im-not-here-to-pump-up-a-stock">Opendoor Skyrockets 314% In A Month Amid Meme Stock Mania: Hedge Fund Manager Who Reaped Windfall Gains Says &#8216;I&#8217;m Not Here To Pump Up A Stock&#8217;</a>
Why It Matters: On the technical front, the S&amp;P 500 index tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) made a <a href="https://www.benzinga.com/markets/equities/25/07/46269226/stocks-just-hit-rare-golden-cross-for-1st-time-since-2023-heres-what-it-means-for-investors">golden cross</a>, where the 50-day moving average surpasses the 200-day moving average, on June 30.
Golden crosses often form during a steady uptrend and cause an additional upswing in the price once the market identifies the signal.
Following the golden cross, the S&amp;P 500 made several new records. On Monday, the index made its sixth consecutive day of record close.
While all technical indicators point toward a bullish trend, the relative strength index of SPY at 76.34 remains in the overbought zone, signaling that it may be poised for a consolidation or reversal in the near term.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29040429/SPY-technical-chart-July-29-1024x576.png" alt="" class="wp-image-1004627" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29040429/SPY-technical-chart-July-29-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29040429/SPY-technical-chart-July-29-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29040429/SPY-technical-chart-July-29-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29040429/SPY-technical-chart-July-29-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/29040429/SPY-technical-chart-July-29.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Price Action: The SPY and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were trading higher in premarket on Tuesday. The SPY was up 0.28% at $638.75, while the QQQ advanced 0.50% to $570.97, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46680436/trumps-eu-deal-good-for-us-markets-say-experts-meta-aapl-pltr-among-likely-winners-see-full-list">Trump&#8217;s EU Deal &#8216;Good For US Markets,&#8217; Say Experts: META, AAPL, PLTR Among Likely Winners — See Full List</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Image Via Shutterstock

AAPL

MSFT

NVDA

S&P 500 Is 'More Concentrated Than Ever:' Here's What $100K In Its Top 10 Stocks Since 2021 Would Be Worth Today

BLCO

Bausch + Lomb Says Ophthalmology And Therapy Publishes Results From Phase 3 Study Assessing Efficacy, Safety Of LUMIFY Preservative Free Redness Reliever Eye Drops Versus LUMIFY Redness Reliever Eye Drops For Reducing Ocular Redness

DRRX

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

BAND

Bandwidth Affirms FY2025 Sales Guidance of $745M-$760M vs $751.524M Est;  Sees Q3 Sales $189M-$191M vs $192.670M Est

<ul>
<li>Transaction expected to close Q1 2026</li>
<li>Proceeds help efficiently fund Duke Energy's $83 billion five-year capital plan</li>
</ul>
CHARLOTTE, N.C., July 29, 2025 /PRNewswire/ -- Duke Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) today announced it reached an agreement to sell its Piedmont Natural Gas Tennessee local distribution company business for $2.48 billion in cash to Spire Inc. ("Spire") – one of the largest publicly traded natural gas companies in the country.
The sale price represents a 1.8x multiple of 2024 year-end rate base and a 24x multiple of 2024 earnings – a significant premium to Duke Energy's common stock. Approximately $800 million of the proceeds will be used to offset debt at Piedmont Natural Gas to maintain its capital structure, and Duke Energy expects to utilize existing tax credits to offset a majority of the cash taxes resulting from the transaction. The remaining net proceeds of $1.5 billion will help efficiently fund Duke Energy's $83 billion five-year capital plan – a plan that is focused on energy modernization investments to deliver value for customers and shareholders.
The transaction is subject to customary closing conditions, including regulatory approval by the Tennessee Public Utility Commission and the expiration or termination of the waiting period under the Hart-Scott-Rodino Act. The sale is expected to close in the first quarter of 2026.
 &nbsp;

Duke Energy Agrees To Sell Its Piedmont Natural Gas Tennessee Local Distribution Company Business For $2.48B In Cash To Spire

Citigroup analyst Leandro Bastos upgrades Afya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFYA#NASDAQ">AFYA</a>) from Sell to Neutral and lowers the price target from $16 to $14.

Upgrades

AFYA

Citigroup Upgrades Afya to Neutral, Lowers Price Target to $14

Macro Notification

General

Novo Nordisk Shares Fall 13% After Cutting 2025 Guidance, Lilly Stock Falls In Sympathy

Bandwidth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0.33 by 14.11 percent. This is a 31.03 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $180.01 million which beat the analyst consensus estimate of $178.88 million by 0.64 percent. This is a 3.69 percent increase over sales of $173.60 million the same period last year.

Earnings

Earnings Beats

Bandwidth Q2 Adj. EPS $0.38 Beats $0.33 Estimate, Sales $180.01M Beat $178.88M Estimate

Raymond James analyst Alexander Sklar upgrades BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) from Market Perform to Outperform and announces $67 price target.

Raymond James Upgrades BlackLine to Outperform, Announces $67 Price Target

Buybacks

BMNR

Bitmine Immersion Technologies Has Approved Stock Repurchase Program To Acquire Up To $1B

SPOT: -9% &#x7C; <a href="https://www.benzinga.com/node/46682528">Spotify Technology shares are trading lower after the company reported worse-than-expected Q2 EPS and issued weaker-than-expected Q3 revenue outlook.</a>
&nbsp;
SRPT: 72% &#x7C; <a href="https://www.benzinga.com/node/46676099">Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients, multiple upgrades this morning</a>
&nbsp;
PYPL: -5% &#x7C; <a href="https://www.benzinga.com/node/46682954">PayPal Holdings Q2 Adj. EPS $1.40 Beats $1.29 Estimate, Sales $8.3B Beat $8.082B Estimate</a>

Movers

Trading Ideas

PYPL

SPOT

SRPT

Market-Moving News for July 29th

Needham analyst Ryan Koontz maintains Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) with a Buy and lowers the price target from $14 to $12.

HLIT

Needham Maintains Buy on Harmonic, Lowers Price Target to $12

Brightstar Lottery (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRSL#NYSE">BRSL</a>) sees FY2025 sales of $2.500 billion vs $2.539 billion analyst estimate.

BRSL

Brightstar Lottery Sees FY2025 Sales $2.500B vs $2.539B Est

Oppenheimer analyst Jay Olson initiates coverage on ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Outperform rating and announces Price Target of $14.

Initiation

ATAI

Oppenheimer Initiates Coverage On ATAI Life Sciences with Outperform Rating, Announces Price Target of $14

WIIM

Eli Lilly shares are trading lower in sympathy with Novo Nordisk, which cut its 2025 guidance.

Novo Nordisk shares are trading lower after the company lowered its 2025 sales outlook, citing reduced growth expectations for Wegovy and Ozempic in the US and weaker Wegovy penetration.

Health Care

Press Releases

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

NextCure Announces Acceptance of IND Application for LNCB74

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

NextCure to Present at 24th Annual Needham Virtual Healthcare Conference

NextCure Provides Business Update and Reports First Quarter 2025 Financial Results

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta

Comments

NextCure

Actualités

Dernières nouvelles pour NextCure (NASDAQ:NXTC) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL